In-animal model |
Antioxidant effects |
Symptom improvement observed by inducing potential function of the CNS and short-term plasticity. |
[30] |
In-animal model |
Antioxidant effects |
Impeded age-related mitochondrial dysfunction by reducing oxidative stress, age-related alterations of mitochondrial dynamics and biogenesis, and activation of PGC-1α/β coactivators. |
[31] |
In-animal model |
Anti-diabetic effects |
An improvement of glucose metabolism in mice with insulin resistant |
[32] |
In-animal model |
Anti-diabetic effects |
Reduction in the serum levels of adiponectin. |
[33] |
In-animal model |
Anti-inflammatory and anti-oxidant effects |
Managed histological and inflammation damage, apoptosis, mitochondrial dysfunction and arsenic-induced hepatotoxicity. |
[34] |
In-animal model |
Antioxidant effect |
Upregulation of nrf2 expression and elevation of GSH and TAC levels. |
[35] |
In-animal model |
Cardioprotective effect |
Controlled the cardiac toxicity induced by 75- and 150-mg/Kg BW aspartme. |
[36] |
In-animal model |
Anti-obesity effect |
Reduction in elevated plasma lipids in obese Zucker rats. |
[37] |
In-animal model |
Immunostimulatory and radioprotective role |
Reduced sperm abnormalities, modified severe tubular degeneration and increased serum testosterone levels. |
[38] |
In-animal model |
Enhanced exercise endurance |
Reduced body fat, increased maximum running time, and elevated mitochondrial biogenesis, oxidative metabolism and fatty acid adsorption. |
[39] |
In-animal model |
Cardioprotective effect |
Inhibited 6-Gy γ-radiation-induced toxicity. |
[40] |
In-animal model |
Antioxidant effect |
Prevented NaAsO2-induced oxidative damage in rat. |
[41] |
In-animal model |
Treatment of muscle atrophy |
Prevented muscle atrophy by inhibiting the ubiquitin proteasome pathway. |
[42] |
In-animal model |
Anti-atherosclerosis effect |
Prevented the production of trimethylamine N-oxide. |
[43] |
In-animal model |
Antioxidant effect |
Decreased the oxidative stress at least in the heart of oophorectomized rats. |
[44] |
In-animal model |
Antioxidant effect |
Decreased acrylamide-toxicity in spleen and thymus tissues in mice. |
[45] |
In-animal model |
Antioxidant effect |
l-carnitine (200 mg/kg BW) for 11 weeks prevented dimethoate toxicity in rats. |
[46] |
In-animal model |
Antioxidant effect |
Reduction in PCC (protein oxidation marker), TBARS (lipid peroxidation marker), caspase-3, DNA fragmentation, cyclobutane pyrimidine dimers, 8-oxo-2′-deoxyguanosine (8-oxo-dG) as well as proinflammatory cytokines IL-1β, IL-6, and TNF-α downregulation, upregulation of PCNA (DNA repair proliferating cell nuclear antigen) protein, removed c-Fos and oxidative stress-sensitive signaling protein p38. |
[47] |